Demonstration of clinical meaningfulness of the integrated Alzheimer’s Disease Rating Scale (iADRS): Association between change in iADRS scores and patient and caregiver health outcomes

Manuscript Number: 

22-0303R1

Author(s): 
Mark Belger, Julie Chandler, Sherie A. Dowsett, Joseph A. Johnston, Dorene M. Rentz, Alette M. Wessels, Youying Yu

Disclosures

Mark Belger

  • Equity:
    minor shareholder in Eli Lilly
    Sponsors:
    Employee of Eli Lilly

Julie Chandler

  • Equity:
    minor stockholder in Eli Lilly and Co
    Sponsors:
    health outcomes scientist in Eli Lilly Research Labs

Sherie A. Dowsett

  • Equity:
    minor stock holder Eli Lilly and Company

Joseph A. Johnston

  • Equity:
    Minor shareholder in Eli Lilly and Company
    Sponsors:
    Full-time employee of Eli Lilly and Company

Dorene M. Rentz

  • Consulting Fees:
    Neurotrack Advisory Board

Alette M. Wessels

  • Equity:
    Employee and shareholder of Eli Lilly and Company
    Sponsors:
    Fulltime paid employee

Youying Yu

  • Equity:
    minor stock holder Eli Lilly and Company
    Sponsors:
    Eli Lilly and Company